Neuroprotective Effect of Coffee and Tea on Haloperidol-InducedParkinson's Disease in Rat Model
DOI:
https://doi.org/10.54361/ljmr.16207Keywords:
Coffee,Tea, Parkinson's disease, Haloperidol, Oxidative stress, GSH.MDAAbstract
Background:Coffee and Tea are very popular beverages in Libyan society. They contain many bioactive substances such as polyphenols and catchiness that could have some effects for instance; antioxidant activity. The way of preparation of tea and coffee drinks are different among society. For example, in Libya tea drink is prepared by boiling the crude of fresh tea for 10 min. Therefore, the method of extraction could influence the type and quality of extracted substances. Aims: The goal of the current study was to examine the neuroprotective properties of coffee and tea beverages made by using traditional Libyan techniqueson Parkinson's disease like symptoms induced by haloperidol.Methods: Different tea and coffee beverages (treatment) were prepared and given to rats in a concentration 10%w/v for 3 consecutive weeks.Tea and coffee beverages were made as Libyans do. At day 21, rats were injected IP with 1mg/kg of haloperidol, afterward, the behavioral and motor parameters for Parkinson’s disease were tested.Results:Coffee and Tea treated groups showed significant improvement (p > 0.05)inthe behavioral activity, and in muscle coordination. Also there was a decrease in oxidation markers as treatment resulted in an elevation of glutathione reductase and decreasing in Malondialdehyde levels. In addition, the histopathological investigation showed a reduction in haloperidol induced damage in substantia nigra.Conclusion:The results showeda possible neuroprotective effect of Coffee and Tea against PD.The mechanism of protection might be due to an antioxidant activity.
Downloads
References
Torquati, L., Peeters, G., Brown, W. J., & Skinner, T. L. (2018). A Daily Cup of Tea or Coffee May Keep You Moving: Association between Tea and Coffee Consumption and Physical Activity. International journal of environmental research and public health, 15(9), 1812. https://doi.org/10.3390/ijerph15091812
Zhang, Y., Yang, H., Li, S., Li, W. D., & Wang, Y. (2021). Consumption of coffee and tea and risk of developing stroke, dementia, and poststroke dementia: A cohort study in the UK Biobank. PLoS medicine, 18(11), e1003830. https://doi.org/10.1371/journal.pmed.1003830
Chin, J. M., Merves, M. L., Goldberger, B. A., Sampson-Cone, A., & Cone, E. J. (2008). Caffeine content of brewed teas. Journal of analytical toxicology, 32(8), 702–704. https://doi.org/10.1093/jat/32.8.702
Forrest, D. (1985). The world tea trade: A survey of the production, distribution and consumption of tea. Cambridge: Woodhead-Faulkner.
Awasom, I. (2011). Commodity of the quarter tea. Journal of Agriculture and Food Information,12(1), 12-22.https://doi.org/10.1080/10496505.2011.540552.
Wang, Y., & Ho, C. T. (2009). Polyphenolic chemistry of tea and coffee: a century of progress. Journal of agricultural and food chemistry, 57(18), 8109–8114. https://doi.org/10.1021/jf804025c.
Sekeroglu, N., Senol, F. S., Orhan, I. E., Gulpinar, A. R., Kartal, M., &Sener, B. (2012). In vitro prospective effects of various traditional herbal coffees consumed in Anatolia linked to neurodegeneration. Food research international, 45(1), 197-203.https://doi.org/10.1016/j.foodres.2011.10.008
Kones, R. (2010). Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition, 25(4), 371–389. https://doi.org/10.1177/0884533610373932
Yadav, S., Gupta, S. P., Srivastava, G., Srivastava, P. K., & Singh, M. P. (2012). Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochemical research, 37(4), 875–884. https://doi.org/10.1007/s11064-011-0682-0
Meissner, W., Hill, M. P., Tison, F., Gross, C. E., &Bezard, E. (2004). Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends in pharmacological sciences, 25(5), 249–253. https://doi.org/10.1016/j.tips.2004.03.003
Rehman, M. U., Wali, A. F., Ahmad, A., Shakeel, S., Rasool, S., Ali, R., Rashid, S. M., Madkhali, H., Ganaie, M. A., & Khan, R. (2019). Neuroprotective Strategies for Neurological Disorders by Natural Products: An update. Current neuropharmacology, 17(3),247–267. https://doi.org/10.2174/1570159X16666180911124605
Saeed, A., Shakir, L., Khan, M., Ali, A., & Zaidi, A. (2017). Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid. Biomedical Research and Therapy, 4(05),1305-1317. https://doi.org/10.15419/bmrat.v4i05.169
Hoffman, D. C., & Donovan, H. (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology, 120(2),128–133. https://doi.org/10.1007/BF02246184
Bogo, V., Hill, T. A., & Young, R. W. (1981). Comparison of accelerod and rotarod sensitivity in detecting ethanol- and acrylamide-induced performance decrement in rats: review of experimental considerations of rotating rod systems. Neurotoxicology, 2(4), 765–787.
Bertelli, J. A., & Mira, J. C. (1995). The grasping test: a simple behavioral method for objective quantitative assessment of peripheral nerve regeneration in the rat. Journal of neuroscience methods, 58(1-2), 151–155. https://doi.org/10.1016/0165-0270(94)00169-h
Jansone,B.,Dzirkale,Z.,Jekabsons,K.,Pilipenko,V.,Beitnere,U.,Māgure,I.,Skumbiņš,R.,Klētnieks,U.,Vanaga,I.,Muceniece,R. &Kluša,V.(2016).Spruce Needle Polyprenols Protect Against Atorvastatin-Induced Muscle Weakness and do not Influence Central Nervous System Functions in Rats. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.,70(1) 13-20. https://doi.org/10.1515/prolas-2016-0003
Barroca, N. C. B., Guarda, M. D., da Silva, N. T., Colombo, A. C., Reimer, A. E., Brandão, M. L., & de Oliveira, A. R. (2019). Influence of aversive stimulation on haloperidol-induced catalepsy in rats. Behavioural pharmacology, 30(2 and 3-Spec Issue), 229–238. https://doi.org/10.1097/FBP.0000000000000462
Deacon, R. M., & Gardner, C. R. (1984). The pull-up test in rats: a simple method for evaluating muscle relaxation. Journal of pharmacological methods, 11(2), 119–124. https://doi.org/10.1016/0160-5402(84)90021-4
Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry, 95(2), 351–358. https://doi.org/10.1016/0003-2697(79)90738-3
Alam, M. N., Bristi, N. J., &Rafiquzzaman, M. (2013). Review on in vivo and in vitro methods evaluation of antioxidant activity. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 21(2), 143–152. https://doi.org/10.1016/j.jsps.2012.05.002
Ellman, G. L., Courtney, K. D., Andres, V., Jr, & Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology, 7, 88–95. https://doi.org/10.1016/0006-2952(61)90145-9
Salvatore, M. F., Pruett, B. S., Dempsey, C., & Fields, V. (2012). Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area. Journal of visualized experiments : JoVE, (66), 4171. https://doi.org/10.3791/4171
Kouli, A., Torsney, K. M., &Kuan, W. L. (2018). Parkinson’s disease: etiology, neuropathology, and pathogenesis. Exon Publications, 3-26.
Jenner P. (2003). Oxidative stress in Parkinson's disease. Annals of neurology, 53 Suppl 3, S26–S38. https://doi.org/10.1002/ana.10483
Waku, I., Magalhães, M. S., Alves, C. O., & de Oliveira, A. R. (2021). Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. The European journal of neuroscience, 53(11), 3743–3767. https://doi.org/10.1111/ejn.15222
Greco, B., Lopez, S., van der Putten, H., Flor, P. J., &Amalric, M. (2010). Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 332(3), 1064–1071. https://doi.org/10.1124/jpet.109.162115
Koppula, S., Kumar, H., More, S. V., Kim, B. W., Kim, I. S., & Choi, D. K. (2012). Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. International journal of molecular sciences, 13(8), 10608–10629. https://doi.org/10.3390/ijms130810608
Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., Jr, & Schwarzschild, M. A. (2001). Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience, 21(10), RC143.https://doi.org/10.1523/JNEUROSCI.21-10-j0001.2001
Perera, J., Tan, J. H., Jeevathayaparan, S., Chakravarthi, S., &Haleagrahara, N. (2011). Neuroprotective effects of alpha lipoic Acid on haloperidol-induced oxidative stress in the rat brain. Cell & bioscience, 1(1), 12. https://doi.org/10.1186/2045-3701-1-12
Jankelowitz, S.K. (2013). Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatric disease and treatment, 9,1371–1380. https://doi.org/10.2147/NDT.S30767.
Shivakumar, B. R., &Ravindranath, V. (1993). Oxidative stress and thiol modification induced by chronic administration of haloperidol. The Journal of pharmacology and experimental therapeutics, 265(3), 1137–1141.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Shaban E. A. Saad, Zuhra M. Mohammed, Issa E. A. Amara, Khaled Aburas, Akram Abrahem (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
